Research programme: CD123 directed therapies - Deltagen

Drug Profile

Research programme: CD123 directed therapies - Deltagen

Alternative Names: Anti-leukaemia stem cell therapies research programme - Deltagen; CD123 targeted drugs research programme - Deltagen

Latest Information Update: 26 Apr 2007

Price : $50

At a glance

  • Originator Deltagen
  • Class Monoclonal antibodies; Small molecules
  • Mechanism of Action Interleukin 3 receptor alpha subunit modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia

Most Recent Events

  • 26 Apr 2007 Discontinued - Preclinical for Acute myeloid leukaemia in USA (unspecified route)
  • 01 Jul 2003 Deltagen has filed a voluntary petition under Chapter 11 of the federal Bankruptcy Code
  • 04 Sep 2002 Deltagen expects to file an IND in the first half of 2003 for an anti-CD123 monoclonal antibody.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top